FDA Accepts sBLA for Obinutuzumab (Gazyva) in Systemic Lupus Erythematosus

The US Food and Drug Administration (FDA) has accepted Genentech's supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva) for the treatment of systemic lupus erythematosus (SLE), the company announced on April 20, 2026.

The filing is based on results from the phase 3 ALLEGORY trial, which demonstrated a statistically significant improvement in disease activity compared with placebo. An FDA decision is expected by December 2026.

"The FDA's sBLA acceptance for Gazyva brings us one step closer to providing a highly effective new treatment option for people living with this unpredictable and potentially life-threatening disease," said Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development at Genentech.¹

If approved, obinutuzumab would become the first anti-CD20 therapy indicated for SLE, a chronic autoimmune disease affecting more than 3 million people worldwide. The drug is already approved in the US and European Union for adults with active lupus nephritis, as well as for several hematological malignancies in approximately 100 countries.¹

ALLEGORY Trial Results

The ALLEGORY study (NCT04963296) is a phase 3, randomized, double-blind, placebo-controlled, multicenter trial that enrolled approximately 300 adults with SLE receiving standard therapy. Participants were randomized 1:1 to receive obinutuzumab or placebo for 52 weeks, followed by an open-label extension period with obinutuzumab for up to 104 additional weeks.¹

The trial met its primary endpoint: 76.7% of patients treated with obinutuzumab plus standard therapy achieved a 4-point or greater improvement on the SLE Responder Index (SRI-4) at 52 weeks, compared with 53.5% in the placebo group (adjusted difference, 23.1%; 95% CI, 12.5-33.6; P < .001).

Obinutuzumab was also superior to placebo across all key secondary endpoints, including British Isles Lupus Assessment Group–based Composite Lupus Assessment (BICLA) response at 52 weeks and sustained glucocorticoid reduction to 7.5 mg/day or less from week 40 through 52.¹

The remission rate at 52 weeks, as defined by the Definition of Remission in SLE (DORIS) criteria, more than doubled among obinutuzumab-treated patients (33.8% vs 13.8%; adjusted difference, 19.9%; 95% CI, 10.6-29.2). The Lupus Low Level Disease Activity State (LLDAS) rate also more than doubled (57.6% vs 25.0%; adjusted difference, 32.6%; 95% CI, 22.3-43.0).

Of note, patients receiving obinutuzumab were significantly less likely to experience a disease flare through week 52, as measured by the BILAG index (hazard ratio, 0.58; 95% CI, 0.40-0.82; P = .002).¹

Safety findings were reported as consistent with the known profile of obinutuzumab, with no new safety signals identified. Key established risks include infusion-related reactions, infections, hepatitis B reactivation, progressive multifocal leukoencephalopathy, neutropenia, and thrombocytopenia.¹

SLE Treatment Landscape

SLE remains a challenging disease to manage, with diagnosis often delayed 2 to 6 years. Repeated flares drive cumulative organ damage, and approximately half of patients develop lupus nephritis within 5 years.¹ Current treatment relies heavily on glucocorticoids, antimalarials, and immunosuppressants, with belimumab (Benlysta) and anifrolumab (Saphnelo) representing the only targeted biologic therapies approved for SLE.² The steroid-sparing effect demonstrated in the ALLEGORY trial is clinically relevant, as long-term glucocorticoid use contributes substantially to morbidity in this population.

Obinutuzumab is a humanized, glycoengineered type II anti-CD20 monoclonal antibody that induces direct B-cell death and enhanced antibody-dependent cellular cytotoxicity. It differs mechanistically from rituximab, the most widely used anti-CD20 agent off-label in lupus, which failed to meet primary endpoints in prior randomized SLE trials.³ Whether obinutuzumab's glycoengineered properties account for superior B-cell depletion and the positive results observed in ALLEGORY warrants further investigation.

Limitations & Next Steps

The ALLEGORY trial's 52-week primary endpoint provides a limited window for evaluating a chronic disease. Long-term durability data from the open-label extension period will be important. Detailed subgroup analyses, including outcomes by race and ethnicity, populations disproportionately affected by SLE, have not yet been fully reported. The ALLEGORY data have also been submitted to the European Medicines Agency for review.¹ Results were published in the New England Journal of Medicine in March 2026 and presented at SLEuro 2026.¹

References

1. Genentech. FDA accepts application for Genentech's Gazyva for the treatment of the most common form of lupus. Press release. April 20, 2026. Accessed April 21, 2026. https://www.businesswire.com/news/home/20260420770652/en/CORRECTING-and-REPLACING-FDA-Accepts-Application-for-Genentechs-Gazyva-for-the-Treatment-of-the-Most-Common-Form-of-Lupus
2. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29.
3. Rovin BH, Furie R, Latinis K, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-1226.